Skip to Content

Pomalyst FDA Approval History

FDA Approved: Yes (First approved February 8, 2013)
Brand name: Pomalyst
Generic name: pomalidomide
Dosage form: Capsules
Company: Bristol-Myers Squibb Company
Treatment for: Multiple Myeloma, Kaposi's Sarcoma

Pomalyst (pomalidomide) is a thalidomide analogue indicated for the treatment of patients with multiple myeloma and AIDS-related and HIV-negative Kaposi sarcoma.

Development Timeline for Pomalyst

May 15, 2020Approval U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma
Feb  8, 2013Approval FDA Approves Pomalyst for Advanced Multiple Myeloma
Oct  3, 2012Celgene Corporation Provides Update on FDA Advisory Committee for Pomalidomide
Apr 27, 2012The International Myeloma Foundation Says Pomalidomide, an Important New Drug for Patients, Has Been Submitted for FDA Approval

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.